Lv3
346 积分 2023-01-09 加入
Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AML
17天前
已完结
Allogeneic hematopoietic stem cell transplantation in elderly patients with AML and MDS: navigating risks and optimizing outcomes
18天前
已完结
A temporal and multinational assessment of acute myeloid leukemia (AML) cancer incidence, survival, and disease burden
18天前
已完结
Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database
1个月前
已完结
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation
1个月前
已完结
Allogeneic hematopoietic stem cell transplantation in elderly patients with AML and MDS: navigating risks and optimizing outcomes
1个月前
已完结
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial
2个月前
已完结
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
2个月前
已完结
Usage of rabbit anti-thymocyte / anti-T-lymphocyte globulins (ATG / ATLG) for hematological malignancies in allogeneic hematopoietic cell transplantation: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines Committee
2个月前
已完结
Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial
2个月前
已完结
皖公网安备34019202002308
